CTS: Erlotinib Equally Effective Alone or in Combination Against Lung Cancer
There were no differences in overall survival between non-small-cell lung cancer patients treated with erlotinib (Tarceva) alone or in combination with standard chemotherapy, researchers found.However, monotherapy with the tyrosine kinase inhibitor showed some benefit for progression-free survival among patients with tumors exhibiting an activating mutation of the epidermal growth factor receptor (EGFR) gene, according to D. Ross Camidge, M.D., of the University of Colorado Health Science Center in Denver.
This entry was posted on Tuesday, November 18th, 2008 at 3:15 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.